Antiretroviral Regimens Reduce Mom-Baby HIV Transmission

Options for pregnant and breast-feeding women, nursing babies all appear effective
By Monica Smith
HealthDay Reporter

WEDNESDAY, June 16 (HealthDay News) -- Various antiretroviral treatment options for lactating mothers and breast-feeding infants appear to reduce mother-to-child transmission of human immunodeficiency virus type-1 (HIV-1), according to two studies in the June 17 issue of the New England Journal of Medicine.

To ascertain the effectiveness of highly active antiretroviral therapy (HAART) in preventing HIV-1 transmission from mother to infant during pregnancy and breast-feeding, Roger L. Shapiro, M.D., of the Beth Israel Deaconess Medical Center in Boston, and colleagues randomized 560 HIV-1-positive women to one of two antiretroviral regimens: either abacavir, zidovudine, and lamivudine, or lopinavir-ritonavir plus zidovudine-lamivudine from 26 to 34 weeks' gestation until planned weaning by six months post-delivery. They found both approaches resulted in a high rate of virologic suppression, with a mother-to-infant transmission rate of 1.1 percent.

Charles S. Chasela, Ph.D., of the University of North Carolina Project in Lilongwe, Malawi, and colleagues randomly assigned 2,369 HIV-1-positive, breast-feeding women and their babies to maternal antiretroviral treatment, infant nevirapine, or no extended postnatal treatment (control group). They found the estimated risk of HIV-1 transmission or death in infants between 2 and 28 weeks of age to be 4.1 percent in the maternal-regimen group and 2.6 percent in the infant-regimen group, compared to 7.0 percent in the control group.

"Health care providers and mothers can ultimately choose the option that best suits their cultural, economic, and individual needs, since there is now evidence for two effective options to prevent the transmission of HIV-1 to infants from their mothers during breast-feeding in resource-limited countries" Chasela and colleagues conclude.

Two authors of the second study disclosed financial ties to Abbott Laboratories and/or GlaxoSmithKline; these and other pharmaceutical and medical device companies provided funding for the study.

Abstract - Shapiro
Full Text
Abstract - Chasela
Full Text
Editorial

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Medical Marijuana: A Hazy State of Affairs for Nurses
AJN, American Journal of Nursing, August 2014
Free access will expire on October 27, 2014.


Understanding nonalcoholic fatty liver disease
Nursing Made Incredibly Easy!, September/October 2014
Free access will expire on October 13, 2014.


Assessing pain in critically ill adults
Nursing2014 Critical Care, July 2014
Free access will expire on October 13, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events